Thrombin Generation Assay for DOAC Bleeding Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current blood coagulation tests, such as prothrombin time (PT-INR) and activated partial thromboplastin time (APTT), are insufficiently sensitive to accurately assess the anticoagulant effect of direct oral anticoagulants (DOACs), leading to inadequate personalized treatment and increased bleeding risks in patients.
Innovation Solution
A blood coagulation test reagent containing the active form of blood coagulation factor XI (FXIa) and tissue factor (TF) is developed, allowing for the measurement of thrombin generation in a biological sample, which provides a more sensitive assessment of bleeding risk and coagulation activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional blood coagulation tests (PT-INR, APTT) are used to monitor DOAC therapy, then the test method is simple and widely available, but the measurement precision is insufficient to accurately assess anticoagulant effect
Solution Approach 1:
The patent changes the chemical parameters of the test reagent by incorporating specific concentrations of FXIa (0.1-100 pM), TF (1-1000 fM), and calcium ions (1-10 mM) to create a highly sensitive thrombin generation assay that can accurately detect DOAC effects, resolving the contradiction between measurement precision and device complexity
Solution Approach 2:
The patent introduces thrombin as an intermediary substance that mediates the coagulation reaction. By measuring thrombin generation rather than directly measuring DOAC concentration, the system achieves high measurement precision while maintaining a relatively simple test format that can be implemented with standard laboratory equipment
2Reliability
If DOACs are used for anticoagulant therapy, then the drug has short half-life and is considered safe with few side effects, but bleeding risk increases in elderly and patients with renal dysfunction
Solution Approach 1:
The patent implements a feedback mechanism by using the highly sensitive thrombin generation test to monitor patient response to DOAC therapy. This allows clinicians to adjust dosing based on actual coagulation status, preventing both thrombosis and excessive bleeding, thereby improving reliability while managing bleeding risk in vulnerable populations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate determination and evaluation of bleeding risk associated with DOACs, facilitating safer and more personalized anticoagulant therapy by optimizing drug dosage for individual patients.
Implementation Method 1
an active form of a blood coagulation factor XI (FXIa); and tissue factor (TF)... measuring an amount of thrombin generated by reacting a biological sample as a test specimen with a test reagent
Implementation Method 2
Thrombin is formed by blood coagulation cascade reactions involving blood coagulation factors with enzyme activities... FIXa required in the reaction is produced by FVIIa-TF activation of FIX
Data Source
AI summary
A highly sensitive blood coagulation test reagent that enables determining and evaluating bleeding risk of direct oral anticoagulants (DOACs) and the like accurately in hemorrhagic diseases, and the like are provided. A blood coagulation test reagent containing: an active form of a blood coagulation factor XI (FXIa); and tissue factor (TF). A blood coagulation test method including a step of measuring the amount of thrombin generated by reacting a biological sample as a test specimen with a test reagent containing: 0.5 pM to 1,000 pM of an active form of a blood coagulation factor XI(FXIa); and 1 fM to 1,000 fM of tissue factor.